Moonlighting function of glycerol kinase causes systems-level changes in rat hepatoma cells

Ganesh Sriram [1,2,§], Lilly S. Parr[1], Lola Rahib[3], James C. Liao[2,3], and

Katrina M. Dipple[1,3,4, *]

[1]Department of Human Genetics, David Geffen School of Medicine at UCLA; [2]Department of Chemical and Biomolecular Engineering and [3]Biomedical Engineering Interdepartmental Program, Henry Samueli School of Engineering and Applied Science; [4]Department of Pediatrics, David Geffen School of Medicine at UCLA, and Mattel Children's Hospital at UCLA, University of California, Los Angeles, California.

[§]Current Affiliation: Department of Chemical and Biomolecular Engineering, University of Maryland; 1208D, Chemical and Nuclear Engineering Bldg. 090, College Park, MD 20742-2111.

*Corresponding author Katrina M. Dipple, David Geffen School of Medicine at UCLA, Departments of Human Genetics and Pediatrics, Gonda 5506B, 695 Charles E. Young Dr. South, Los Angeles, CA 90095-7088. *Phone:* (310)-825-1997; *Fax:* (310)-794-5446; *Email:* kdipple@mednet.ucla.edu.

Abstract

Glycerol kinase (GK) is an enzyme with diverse (moonlighting) cellular functions. *GK* overexpression affects central metabolic fluxes substantially; therefore, to elucidate the mechanism underlying these changes, we employed a systems–level evaluation of *GK* overexpression in H4IIE rat hepatoma cells. Microarray analysis revealed altered expression of genes in metabolism (central carbon and lipid), which correlated with previous flux analysis, and of genes regulated by the glucocorticoid receptor (GR). Oil Red O staining showed that *GK* overexpression leads to increased fat storage in H4IIE cells. Network component analysis revealed that activities of peroxisome proliferator-activated receptor α, GR, and seven other transcription factors were altered by *GK* overexpression. The increased activity of GR was experimentally verified by quantitative RT-PCR of GR-responsive genes in the presence and absence of the glucocorticoid agonist, dexamethasone. This systems biology approach further emphasizes GK's essential role in central and lipid metabolism and experimentally verifies GK's alternative (moonlighting) function of affecting GR transcription factor activity.

Keywords

Introduction

Glycerol kinase (GK) is a key metabolic enzyme at the interface of carbohydrate and lipid metabolism (Dipple et al., 2001b). In humans, it has a particularly important role in the liver, where its activity is highest (MacLennan et al., 2006). Apart from its biochemical (enzymatic, metabolic) function of catalyzing the phosphorylation of glycerol to glycerol-3-phosphate, GK has other protein activities and is therefore, a "moonlighting" protein (Sriram et al., 2005). For example, in rat liver, GK also functions as the ATP-stimulated translocation promoter (ASTP) and enhances the nuclear binding of the activated glucocorticoid (G)-glucocorticoid receptor (GR) complex (G-GRC) (Okamoto et al., 1984). The G-GRC binds to glucocorticoid response elements in the promoters of GR-responsive genes and regulates the expression levels of those genes (Le et al., 2005; Schoneveld et al., 2004). GK has additional functions including binding to histones (Okamoto et al., 1989), interacting with porin (voltage-dependent anion channel on the outer surface of the outer mitochondrial membrane) (Ostlund et al., 1983), and playing a role in apoptosis (Martinez-Agosto and McCabe, 2006). Furthermore, GK has a role in insulin sensitivity as it is overexpressed in response to thiazolidinediones, common drugs to treat type 2 diabetes mellitus (Lee et al., 2005). The overexpression of GK relieves insulin resistance (Guan et al., 2002; Tordjman et al., 2003), and a *GK* missense mutation predisposes individuals to obesity, insulin resistance and type 2 diabetes mellitus (Gaudet et al., 2000).

GK is the causative gene in glycerol kinase deficiency (GKD), an X-linked, single gene, inborn error of metabolism (Dipple et al., 2001b). In individuals affected by GKD, no correlation has been found between genotype and clinical phenotype despite extensive studies (Dipple et al., 2001b; Sargent et al., 2000). We have proposed that the glycerol

phosphorylating activity of GK may not, by itself, explain the complexity of GKD (Dipple and McCabe, 2000a; Dipple and McCabe, 2000b; Dipple et al., 2001a; Dipple et al., 2001b), and therefore, GK's roles in other metabolic pathways and cellular processes (moonlighting activities) need to be examined.

We have previously shown that *Gyk* (the mouse ortholog of GK) deletion in mice alters gene expression extensively in liver (MacLennan et al., 2006), brown fat (Rahib et al., 2007) and muscle (Rahib et al., 2009). The genes affected included those involved in central carbon metabolism and lipid metabolism, which is expected given GK's enzymatic/biochemical role at the interface of carbohydrate and fat metabolism. However, many other biological groups were significantly altered including insulin signaling, insulin resistance, apoptosis, steroid biosynthesis, and cell cycle arrest (MacLennan et al., 2006; Rahib et al., 2007; Rahib et al., 2009). This suggests that the changes seen may be due in part, to GK's moonlighting functions such as its role as ASTP, which has the potential to affect gene expression through the GR. In addition, we have previously demonstrated that *GK* overexpression globally alters fluxes through central carbon metabolism (Sriram et al., 2008). Notably, the flux through the oxidative pentose phosphate pathway (oxPPP) in the *GK*-overexpressing cell lines was two-fold higher than wild type. Since this pathway contributes cytosolic NADPH toward lipogenesis, we hypothesize that *GK* overexpression leads to higher lipogenic activity.

Therefore, we hypothesize that GK lies in a transcriptional network wherein it is regulated by upstream transcription factors and we hypothesize that GK effects the activities of downstream transcription factors (Fig. 1). Upstream transcription factors such

as hepatocyte nuclear factor (HNF) 4α (Stepanian et al., 2003), peroxisome proliferator-activated receptor (PPAR) α (Patsouris et al., 2004) , and PPAR γ co-activator (PGC) 1α (Finck and Kelly, 2006) control the expression of GK. There is evidence that GK, in turn, directly or indirectly effects the expression or activity of downstream transcription factors such as the GR (due to its ASTP role; Okamoto et al., 1993; Okamoto et al., 1989), HNF 4α, PPAR α, sterol regulatory element binding protein (SREBP) 1a, SREBP 2, and carbohydrate response element binding protein (ChREBP) (MacLennan et al., 2006; Rahib et al., 2007) which regulate their target genes.

To test the above hypotheses, we performed cDNA microarray analysis of *GK*-overexpressing (GK2) H4IIE and wild type (WT) cell lines. Network analyses included statistical clustering analyses and network component analysis (NCA). The statistical clustering analyses revealed several genes and transcription factors whose expression/activity was affected by *GK* overexpression. These results supported our previous metabolic flux analyses (Sriram et al., 2008). We also showed experimentally that GK2 cells stored more fat, which is consistent with GK's role in adipogenesis. NCA, a mathematical technique that interprets microarray data to quantitatively infer hidden transcription factor activities (Galbraith et al., 2006; Liao et al., 2003), estimated that the activities of at least nine transcription factors were altered by *GK* overexpression. Of these, the most interesting result was increased activity of the GR, as this is directly related to the ASTP activity of GK. Furthermore, we experimentally verified the NCA results of increased GR transcription factor activity using a dexamethasone (a glucocorticoid agonist) dose response experiment. This experiment demonstrated that the *GK*-overexpressing cell lines indeed exhibit a higher level of expression of known GR responsive genes. This work

furthers our previous studies on GK's central role in metabolism and transcription, and provides insights into the multiple protein functions of this protein as well as a basis for understanding the complexity of the single gene disorder GKD.

Materials and methods

H4IIE cell culture

H4IIE, a rat hepatoma cell line, was obtained from American Type Culture Collection (Manassas, VA). The *GK*-overexpressing cell line GK2 was derived from this line as previously described (Sriram et al., 2008). Cells were maintained at 37°C in a humidified atmosphere in culture medium previously described (Sriram et al., 2008).

Oil Red O staining

For lipid visualization and quantification through Oil Red O staining, the WT and GK2 cells were fixed with 10% formalin, stained with 0.7% Oil Red O solution (Sigma, St. Louis, MO) and the resulting absorbance at 510 nm was quantified.

RNA isolation and purification

RNA was isolated from the cell lines by using the RNeasy kit (Qiagen, Valencia, CA), purified by using the RNeasy MinElute kit (Qiagen) and DNAse treated (Turbo DNA-free, Ambion, Austin, TX) as per manufacturer's instructions. Total RNA was quantified on a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE).

cDNA synthesis, hybridization, and microarray analysis

cDNA synthesis and hybridization to the GeneChip rat genome 230 2.0 array (Affymetrix, Santa Clara, CA) were performed as described previously (MacLennan et al., 2006). This array contained 31042 probesets. Microarray data were analyzed, quantified, and annotated by using the DNA-Chip Analyzer (dChip) software (Li and Wong, 2003).

Clustering and statistical analyses

We employed principal component analysis (PCA) (an unsupervised learning technique to cluster genes) and supervised hierarchical clustering (Jaluria et al., 2007; Lee et al., 2007) for initial statistical analysis of the microarray data. To perform PCA, the 2902 "most varying probesets" were selected with the following criteria: coefficient of variance between 0.3 and 10.0 and present call > 20%. Supervised hierarchical clustering was performed by filtering out differentially regulated genes that met the following criteria: fold change > 1.5 between baseline (WT) and experimental (GK2), absolute difference in the expression level between baseline and experimental > 100, $p < 0.05$, and present call > 20%. Clustering "heat maps" for genes in two biological categories ([a] cellular metabolic processes, and [b] lipid metabolic processes and lipid transport) were then generated using dChip.

p-values of differences between means were determined by the Student's t-test. We determined the false discovery rate (FDR) for false positives by the following two methods and obtained similar results. First, we used a method reported by Giordano et al. (2006), and we obtained an FDR value of 38% for a p-value cut-off of 0.05. The second approach

was using tools publicly available at http://www.rowett.ac.uk/~gwh/fdr.html, and we obtained an FDR value of 29% for a *p*-value cut-off of 0.05.

Gene expression assay by quantitative RT-PCR

Gene expression was confirmed by quantitative real time PCR (RT-PCR) as described previously (Rahib et al., 2007) with β-actin or 18s rRNA (Applied Biosystems, Foster City, CA) used as an endogenous control. Fold changes in mRNA expression were calculated using the $2^{-\Delta\Delta CT}$ method (Livak and Schmittgen, 2001; Rahib et al., 2007).

Network component analysis (NCA)

NCA (Liao et al., 2003) was performed by using the NCA toolbox. To obtain connectivity information between transcription factors and genes for NCA, transcription factors important in rat liver were identified. Relationships between these transcription factors and genes were determined from the literature, on the basis of which an initial connectivity matrix with 14 transcription factors and 62 genes was constructed. The NCA toolbox combined the microarray data and the connectivity information to obtain transcription factor activities and control strengths.

ASTP activity assay (experimental verification of GK's moonlighting activity)

The ASTP activity of GK was assayed by quantifying the gene expression level of known GR-responsive genes phosphoenolpyruvate carboxykinase (*PEPCK*) and tyrosine aminotransferase (*TAT*) (Herzog et al., 2004) through quantitative RT-PCR.

Replicates and statistical analyses

We used two biological replicates for the microarray analysis. Two to four biological replicates, each of which had two to three technical replicates, were used for qPCR and the dexamethasone dosage experiments (to verify the higher moonlighting activity of GK in the GK-overexpressing cells). Statistical analyses (PCA, p-values, false discovery rate) were performed as described above.

Results

To investigate the effects of *GK* overexpression on gene regulation, we constructed a human *GK*-overexpressing stable H4IIE rat hepatoma cell line GK2, as described previously (Sriram et al., 2008). The expression of human *GK* in the GK2 cells was significantly higher than WT (1.76 ± 0.03 fold, $p < 0.01$; data not shown), which is consistent with our previous work (Sriram et al., 2008). We performed microarray analysis and NCA of WT and GK2 cells. This analysis revealed altered expressions of (central carbon and lipid) metabolic genes, which correlated with previous flux analysis, as well as of genes regulated by the glucocorticoid receptor (GR). NCA interpreted the microarray data to infer that *GK* overexpression alters the activities of the GR and eight other transcription factors. Using a dexamethasone (GR agonist) dose response experiment and quantitative RT-PCR of GR-responsive genes, we experimentally verified the NCA prediction that *GK* overexpression leads to increased GR activity.

Microarray analysis of WT and GK2 cell lines

Principal component analysis (PCA) on the 2,902 most varying probesets in the microarray data revealed that the GK2 cells clearly clustered away from WT cells (Supplemental Material 1), indicating that their global gene expression profiles were significantly different. The average linkage clustering dendrogram obtained from PCA also confirmed that the GK2 cells clustered away from WT (Supplemental Material 1).

Supervised clustering of the microarray data (tabulated in Supplemental Material 2) revealed that 228 genes were differentially regulated in GK2 (> or < 1.5-fold) compared to WT ($p < 0.05$; Fig 2, Table 1). dChip analysis revealed that GK2 cells differ substantially from the WT in two significant biological categories: cellular metabolic processes (Fig. 2a), and lipid metabolic processes and lipid transport (Fig. 2b). Additionally, sterol regulatory element binding factor 1 (*SREBF*) 1, which codes for the lipogenic transcription factor SREBP1 was upregulated in the GK2 cell line. This points to an important role for GK in lipogenesis.

Several gene expression levels were consistent with the results of our previous metabolic flux analysis on these cell lines (Sriram et al., 2008). For instance, genes coding for the anaplerotic enzymes *PEPCK*1 and malic enzyme (*ME*) 1 were upregulated 1.29-fold and 1.31-fold respectively, in GK2 cells compared to WT ($p < 0.05$, Table 1). Furthermore, lactate dehydrogenase B was downregulated 32.7-fold, which is consistent with lower lactate production observed in GK2 cells (Sriram et al., 2008). Glucose-6-phosphate dehydrogenase (*G6PDH*, which codes for the rate-limiting enzyme of the oxPPP) was

upregulated 1.25-fold, which agrees with the higher oxPPP flux observed in GK2 cells (Sriram et al., 2008).

Several genes that are either classical GR-responsive genes (Mittelstadt and Ashwell, 2003; Schoneveld et al., 2004) or newly elucidated targets of the GR in liver (Phuc Le et al., 2005) were differentially regulated in GK2 cells compared to WT ($p < 0.05$; Table 1, bolded entries). For example, glutamine synthetase/glutamate ammonia ligase (*GluL*) was downregulated 1.64 fold; ATP-binding cassette, sub-family A, member 1 (*ABC*1) was upregulated 1.18-fold; *PEPCK* was upregulated 1.29-fold; insulin-like growth factor binding protein (*IGFBP*) 1 was upregulated 1.30-fold; *TyrAT* was upregulated 1.69-fold; adrenomedullin was upregulated 2.06-fold; alcohol dehydrogenase (*ADH*) 1 was upregulated 2.17-fold; and serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (*Serpina*1*a*) was upregulated 2.56-fold in GK2 cells compared to WT (p<0.05, Table 1). Furthermore, 11β-hydroxysteroid dehydrogenase type 1, which catalyzes the conversion of biologically inactive 11-keto derivatives to active glucocorticoids in liver and other tissues, was upregulated 2.31-fold in GK2 cells ($p < 0.05$, Table 1). Additionally, insulin signaling-related genes such as *IGFBP*1 (1.3-fold) and alpha-2-HS-glycoprotein (1.92-fold) were upregulated in GK2 cells.

Verification of gene expression by quantitative RT-PCR

Quantitative RT-PCR verified the expression levels of ten genes that were determined by microarray analysis to be differentially regulated (Fig. 3), including the upregulated GR-responsive genes *IGFBP*1, *TyrAT*, *ADH*, *IDH*, and *PEPCK*1 and the upregulated lipogenic genes *PEPCK*1, *G6PDH*, *SREBF*1, and *ME*1. The expression levels of all

these genes as determined by quantitative RT-PCR were greater in magnitude than those quantified from the microarray, but agreed in direction. The GR-responsive gene *GluL* was downregulated in GK2 cells according to one probeset on the microarray (1367632_at), and upregulated according to two probesets (1389426_at and 1375569_at). This is most likely due to cross-reactivity of these probesets, as has been observed previously (MacLennan et al., 2006). Therefore, quantitative RT-PCR established that *GluL* was downregulated in GK2 cells as indicated by the probeset 1367632_at.

GK-overexpressing cells have higher lipid reserves than wild type

To experimentally verify the role of GK in lipogenesis, Oil Red O staining was performed and revealed that GK2 cells stored more fat and therefore had higher lipid reserves than WT cells (Fig. 4a). Quantification of the lipid content in the GK2 cells showed that the GK overexpressing cells had almost twice as much fat stored (1.89 ± 0.44 times, $p < 0.01$, Fig. 4b), compared to WT.

Network component analysis (NCA)

We used NCA (Galbraith et al., 2006; Liao et al., 2003) to deduce transcription factor activities that were altered by *GK* overexpression. NCA is a mathematical technique that interprets microarray data to quantitatively calculate transcription factor activity changes hidden in the data. To perform NCA, nine potential transcription factors (SREBP1a, ChREBP, Sp1, HNF1α, HNF4α, PPARα, PPARγ, liver X receptor [LXR]α, CCAAT-box/enhancer binding protein [C/EBP]β, , and GR) were identified based on the above results, together with 62 targets of some or all of these transcription factors that were

differentially regulated in GK2 cells (filtered as explained in Methods). An initial

"connectivity matrix" was constructed from this information and from gene regulation

information in the literature (matrix and corresponding literature references are shown in

Supplemental Material 3A and 3B). We intended to include five more important

transcription factors (SREBP1c, SREBP2, Zhx2, GADD153, and PPARγ) but had to delete

them from the matrix as they did not satisfy the mathematical criteria required for NCA

(Liao et al., 2003) to generate an identifiable network.

NCA deduced that *GK* overexpression leads to increased activity of several

transcription factors including ChREBP, Sp1, HNF1α, HNF4α, PPARα, LXRα, and GR and

decreased activity of SREBP1a and CEBPβ (Fig. 5). Importantly, the NCA results indicated

that the activities of both PPARα and GR were higher in GK2 than in WT ($p < 0.05$; Fig. 5).

The entire output of NCA, including the deduced connectivity between transcription factors

and genes, is shown in Supplementary Material 4.

These altered transcription factor activities resulting from NCA can potentially

explain some gene expression trends observed in the microarray data (see Discussion). The

activity of SREBP1a was deduced to be lower in GK2 cells compared to WT, contrary to the

trend in its gene expression. This surprising result may perhaps reflect the dependence of

the (NCA-estimated) transcription factor activity on post-translational events in addition to

the mRNA level (MacLennan et al., 2006). The SREBP1a result illustrates the power of NCA

over microarray data analysis programs that do not estimate transcription factor activity.

This result could have been tested experimentally by employing a recently reported SREBP

assay (Chatterjee et al., 2009), which involves the endogenous SREBP-mediated regulation

of a promoter that drives a luciferase gene reporter construct. However, for this work, we chose to focus on GR activity because it is directly linked to the moonlighting function of GK, whereas SREBP activity is not. Therefore, we experimentally verified the NCA deduction that GR activity in *GK*-overexpressing cells is higher (as explained below).

Experimental verification of higher GR transcription factor activity in GK-overexpressing cells

To experimentally verify the NCA deduction that the transcription factor activity of the GR was indeed higher in GK2 cells than the wild type, we quantified the expression level of the known GR-responsive gene *PEPCK* (Herzog et al., 2004) in independent experiments. We exposed WT and GK2 cells to two different doses (200 nM and 500 nM) of the glucocorticoid agonist dexamethasone for two different exposure times (1 h and 2 h). The dose response curves for 1 h exposure (Fig. 6a) and 2 h exposure (Fig. 6b) to dexamethasone clearly show that GK2 cells responded to dexamethasone better than WT cells. This verifies that the transcription factor activity of the GR is higher in GK2 cells than in WT. This dose response curve was valid up to 19 h (data not shown).

Furthermore, the effect of dexamethasone addition on GR transcription factor activity in WT cells was mimicked by *GK* overexpression. Treatment of WT cells with 200 nM dexamethasone for increasing exposure times enhanced the expression of GR-responsive genes *TAT* and *PEPCK* in WT cells (Fig. 7). For a 2 h exposure, the expression of *TAT* in WT cells was significantly higher (3.47 ± 0.12 times) than that of dexamethasone-untreated WT cells ($p < 0.05$; Fig. 7a). This trend is analogous to the effect of *GK* overexpression on *TAT* expression, as the expression level of *TAT* was 2.82 ± 0.12 times

14

higher in GK2 cells than WT ($p < 0.05$; Fig. 7a). Similar results were also observed for the GR-responsive gene *PEPCK*, in which case WT cells required a 5.5 h dose of 200 nM dexamethasone to significantly increase *PEPCK* expression (Fig. 7b). Therefore, *GK* overexpression mimics the effect of exposure to the glucocorticoid agonist dexamethasone on GR transcriptional activity.

Discussion

GK is an important metabolic enzyme with moonlighting activities and its deletion causes a single gene disorder exhibits several complexities (Dipple and McCabe, 2000a; Dipple and McCabe, 2000b; Dipple et al., 2001a; Dipple et al., 2001b). A fundamental understanding of GK's role in mammalian cells requires understanding its moonlighting activities and therefore requires a systems biology approach. Previously we used isotope-assisted metabolic flux analysis (Sriram et al., 2004) to demonstrate, that *GK* overexpression in rat liver cells substantially alters fluxes in central carbon metabolism (Sriram et al., 2008), particularly in the oxPPP, suggesting increased lipogenesis. In this work, we performed microarray analysis and NCA to study how *GK* overexpression affects gene expression and transcription factor activity. The current study not only substantiated our previous metabolic flux study, but also indicated a role for GK's moonlighting (ASTP) activity in transcription. Furthermore, we observed altered expressions of many metabolic genes (*G6PDH*, lactate dehydrogenase B, *IDH*, *PEPCK*1, *ME*1) in *GK*-overexpressing cells. This substantiates our previous study on metabolic flux alterations caused by *GK* overexpression (Sriram et al., 2008) and suggests that the metabolic flux patterns observed in our previous work are due, at least in part, to transcriptional regulation of the relevant genes. Our observation of differential expression of genes involved in metabolism, lipid

15

metabolism and insulin signaling genes in *GK*-overexpressing cells is consistent with our previous studies on *GK*-deleted mice (MacLennan et al., 2006; Rahib et al., 2007; Rahib et al., 2009). We also observed evidence of increased lipid synthesis in GK2 cells as determined by Oil Red O staining, which substantiates our earlier hypothesis (Sriram et al., 2008) that the increased oxPPP flux in *GK*-overexpressing cells contributes cytosolic NADPH toward lipogenesis.

Many GR-responsive genes were also differentially expressed in GK2 cells. NCA estimated that at least nine transcription factor activities, including that of the GR, were altered by *GK* overexpression. These results substantiate the use of systems techniques such as NCA to interpret high-throughput microarray data and quantify transcription factor activities hidden in the data. First, the increased transcription activity of the GR in GK2 cells is ambiguous from the microarray results since genes known to be positively regulated by the GR were both upregulated (e.g. *PEPCK*, *TAT*, *ADH*) and downregulated (*GluL*) in the microarray. This is not surprising, since transcription factors other than the GR could also regulate these genes and the overall gene expression is due to the net influence of all the relevant transcription factors. Therefore, NCA performed an important role in decoupling the effects of competing transcription factors that regulated the differentially expressed genes. In addition, this work confirms the moonlighting ASTP activity (Okamoto et al., 1993; Okamoto et al., 1989; Sriram et al., 2005) of GK. Second, the activity of SREBP1a was estimated to be lower in GK2 cells than in WT, contrary to its gene expression. This could be ascribed to transcription factor activity being regulated at the post-translational level (MacLennan et al., 2006), but it would not have been revealed without the use of NCA.

16

NCA deduced that *GK* overexpression results in increased transcription factor activity of PPARα. This may explain the increased oxPPP flux due to *GK* overexpression (Sriram et al., 2008), as PPARα is an important transcription factor for *G6PDH*, the gene coding for the rate limiting enzyme of the oxPPP (Xu et al., 2004). The increased transcription factor activity of the GR due to *GK* overexpression was an interesting result, as GK facilitates the nuclear translocation of the GR in its moonlighting role as ASTP. We experimentally verified this NCA result by measuring GR transcription factor activity via the expression of its target gene *PEPCK*. We also verified that *GK* overexpression mimics the effect of the glucocorticoid agonist dexamethasone on GR transcription factor activity. To the extent of our knowledge, this is the first work where a deduction of NCA has been experimentally verified in a mammalian system.

Conclusions and summary

This study confirms our previous metabolic flux analysis elucidating GK's role in central metabolism. In addition, we have confirmed GK's role in the transcription of GR-responsive genes. *GK* overexpression in rat hepatoma cells causes increased lipid storage and increased expression of genes important in lipogenesis, which was hypothesized by us previously (Sriram et al., 2008) and this may be related to GK's role in diabetes and insulin sensitivity. *GK* overexpression also causes increased GR transcription factor activity, which is directly related to GK's moonlighting role as ASTP (Okamoto et al., 1993; Okamoto et al., 1984) (Sriram et al., 2005). Together with our previous metabolomic study (Sriram et al., 2008), this transcriptomic study with experimental verification provides an improved understanding of GK's regulatory role and provides insight into the pathogenesis of GKD. In addition, this work shows the importance of understanding the moonlighting functions

(or all the cellular protein activities) of metabolic enzymes in understanding the pathogenesis of single gene inborn errors of metabolism (Sriram et al., 2005).

Acknowledgments

References

Chatterjee, S., Szustakowski, J. D., Nanguneri, N. R., Mickanin, C., Labow, M. A., Nohturfft, A., Dev, K. K., Sivasankaran, R., 2009. Identification of novel genes and pathways regulating SREBP transcriptional activity. PLoS ONE. 4, e5197-e5197.

Dipple, K. M., McCabe, E. R., 2000a. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol Genet Metab. 71, 43-50.

Dipple, K. M., McCabe, E. R., 2000b. Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet. 66, 1729-35.

Dipple, K. M., Phelan, J. K., McCabe, E. R., 2001a. Consequences of complexity within biological networks: robustness and health, or vulnerability and disease. Mol Genet Metab. 74, 45-50.

Dipple, K. M., Zhang, Y. H., Huang, B. L., McCabe, L. L., Dallongeville, J., Inokuchi, T., Kimura, M., Marx, H. J., Roederer, G. O., Shih, V., Yamaguchi, S., Yoshida, I., McCabe, E. R., 2001b. Glycerol kinase deficiency: evidence for complexity in a single gene disorder. Hum Genet. 109, 55-62.

Finck, B. N., Kelly, D. P., PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. Vol. 116. Am Soc Clin Investig, 2006, pp. 615-622.

Galbraith, S. J., Tran, L. M., Liao, J. C., 2006. Transcriptome network component analysis with limited microarray data. Bioinformatics. 22, 1886-1894.

Gaudet, D., Arsenault, S., Perusse, L., Vohl, M. C., St-Pierre, J., Bergeron, J., Despres, J. P., Dewar, K., Daly, M. J., Hudson, T., Rioux, J. D., 2000. Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system by use of a simple genetic trait. Am J Hum Genet. 66, 1558-68.

Giordano, T. J., Au, A. Y. M., Kuick, R., Thomas, D. G., Rhodes, D. R., Wilhelm, K. G., Vinco, M., Misek, D. E., Sanders, D., Zhu, Z., Ciampi, R., Hanash, S., Chinnaiyan, A., Clifton-Bligh, R. J., Robinson, B. G., Nikiforov, Y. E., Koenig, R. J., 2006. Delineation, functional validation, and bioinformatic

evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARg translocation. Clinical Cancer Research. 12, 1983-1993.

Guan, H. P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M., Lazar, M. A., 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. 8, 1122-8.

Herzog, B., Hall, R. K., Wang, X. L., Waltner-Law, M., Granner, D. K., 2004. Peroxisome Proliferator-Activated Receptor ? Coactivator-1a, as a Transcription Amplifier, Is Not Essential for Basal and Hormone-Induced Phosphoenolpyruvate Carboxykinase Gene Expression. Molecular Endocrinology. 18, 807-819.

Jaluria, P., Betenbaugh, M., Konstantopoulos, K., Frank, B., Shiloach, J., 2007. Application of microarrays to identify and characterize genes involved in attachment dependence in HeLa cells. Metabolic Engineering. 9, 241-251.

Le, P. P., Friedman, J. R., Schug, J., Brestelli, J. E., Parker, J. B., Bochkis, I. M., Kaestner, K. H., 2005. Glucocorticoid receptor-dependent gene regulatory networks. PLoS Genetics. 1, e16-e16.

Lee, D. H., Park, D. B., Lee, Y. K., An, C. S., Oh, Y. S., Kang, J. S., Kang, S. H., Chung, M. Y., 2005. The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats. Metabolism. 54, 1282-9.

Lee, Y. Y., Wong, K. T. K., Nissom, P. M., Wong, D. C. F., Yap, M. G. S., 2007. Transcriptional profiling of batch and fed-batch protein-free 293-HEK cultures. Metabolic Engineering. 9, 52-67.

Li, C., Wong, W. H., 2003. DNA-Chip Analyzer (dChip). In: Parmigiani, G., Garrett, E., Irizarry, R., Zeger, S., Eds.), The analysis of gene expression data: methods and software. Springer, New York, pp. 120-141.

Liao, J. C., Boscolo, R., Yang, Y. L., Tran, L. M., Sabatti, C., Roychowdhury, V. P., 2003. Network component analysis: reconstruction of regulatory signals in biological systems. Proc Natl Acad Sci U S A. 100, 15522-7.

Livak, K. J., Schmittgen, T. D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. Methods. 25, 402-408.

MacLennan, N. K., Rahib, L., Shin, C., Fang, Z., Horvath, S., Dean, J., Liao, J. C., McCabe, E. R., Dipple, K. M., 2006. Targeted disruption of glycerol kinase gene in mice: expression analysis in liver shows alterations in network partners related to glycerol kinase activity. Hum Mol Genet. 15, 405-15.

Martinez-Agosto, J. A., McCabe, E. R. B., 2006. Conserved family of glycerol kinase loci in *Drosophila melanogaster*. Molec Genet Metabol. 88, 334-345.

Mittelstadt, P. R., Ashwell, J. D., 2003. Disruption of Glucocorticoid Receptor Exon 2 Yields a Ligand-Responsive C-Terminal Fragment that Regulates Gene Expression. Mol Endocrinol. 17, 1534-1542.

Okamoto, K., Hirano, H., Isohashi, F., 1993. Molecular cloning of rat liver glucocorticoid-receptor translocation promoter. Biochem Biophys Res Commun. 193, 848-54.

Okamoto, K., Isohashi, F., Horiuchi, M., Sakamoto, Y., 1984. An ATP-stimulated factor that enhances the nuclear binding of "activated" receptor-glucocorticoid complex. Biochem Biophys Res Commun. 121, 940-5.

Okamoto, K., Isohashi, F., Ueda, K., Sakamoto, Y., 1989. Properties of an adenosine triphosphate-stimulated factor that enhances the nuclear binding of activated glucocorticoid-receptor complex: binding to histone-agarose. Endocrinology. 124, 675-80.

Ostlund, A. K., Gohring, U., Krause, J., Brdiczka, D., 1983. The binding of glycerol kinase to the outer membrane of rat liver mitochondria: its importance in metabolic regulation. Biochem Med. 30, 231-45.

Patsouris, D., Mandard, S., Voshol, P. J., Escher, P., Tan, N. S., Havekes, L. M., Koenig, W., Marz, W., Tafuri, S., Wahli, W., 2004. PPARa governs glycerol metabolism. Journal of Clinical Investigation. 114, 94-103.

Phuc Le, P., Friedman, J. R., Schug, J., Brestelli, J. E., Parker, J. B., Bochkis, I. M., Kaestner, K. H., 2005. Glucocorticoid Receptor-Dependent Gene Regulatory Networks. PLoS Genetics. 1, e16.

Rahib, L., MacLennan, N. K., Horvath, S., Liao, J. C., Dipple, K. M., 2007. Glycerol kinase deficiency alters expression of genes involved in lipid metabolism, carbohydrate metabolism, and insulin signaling. Eur J Hum Genet. 15, 646-57.

Rahib, L., Sriram, G., Harada, M. K., Liao, J. C., Dipple, K. M., 2009. Transcriptomic and network component analysis of glycerol kinase in skeletal muscle using a mouse model of glycerol kinase deficiency. Mol Genet Metab. 96, 106-12.

Sargent, C. A., Kidd, A., Moore, S., Dean, J., Besley, G. T., Affara, N. A., 2000. Five cases of isolated glycerol kinase deficiency, including two families: failure to find genotype:phenotype correlation. J Med Genet. 37, 434-41.

Schoneveld, O. J., Gaemers, I. C., Lamers, W. H., 2004. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta. 1680, 114-28.

Sriram, G., Fulton, D. B., Iyer, V. V., Peterson, J. M., Zhou, R., Westgate, M. E., Spalding, M. H., Shanks, J. V., 2004. Quantification of compartmented metabolic fluxes in developing soybean embryos by employing biosynthetically directed fractional ^{13}C labeling, two-dimensional [^{13}C, ^{1}H] nuclear magnetic resonance, and comprehensive isotopomer balancing. Plant Physiol. 136, 3043-3057.

Sriram, G., Martinez, J. A., McCabe, E. R. B., Liao, J. C., Dipple, K. M., 2005. Single-gene disorders: What role could moonlighting enzymes play? Am J Hum Genet. 76, 911-924.

Sriram, G., Rahib, L., He, J.-S., Campos, A. E., Parr, L. S., Liao, J. C., Dipple, K. M., 2008. Global metabolic effects of glycerol kinase overexpression in rat hepatoma cells. Molecular Genetics and Metabolism. 93, 145-159.

Stepanian, S. V., Huyn, S. T., McCabe, E. R. B., Dipple, K. M., 2003. Characterization of the human glycerol kinase promoter: identification of a functional HNF-4a binding site and evidence for transcriptional activation. Molecular Genetics and Metabolism. 80**,** 412-418.

Tamura, K., Ono, A., Miyagishima, T., Nagao, T., Urushidani, T., 2006. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. Journal of Toxicological Sciences. 31**,** 471-490.

Tordjman, J., Chauvet, G., Quette, J., Beale, E. G., Forest, C., Antoine, B., 2003. Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. J Biol Chem. 278**,** 18785-90.

Xu, J., Chang, V., Joseph, S. B., Trujillo, C., Bassilian, S., Saad, M. F., Lee, W. N., Kurland, I. J., 2004. Peroxisomal proliferator-activated receptor α deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology. 145**,** 1087-95.

Figure legends

Figure 1. Hypothesized transcriptional network of glycerol kinase (GK). Upstream transcription factors such as hepatocyte nuclear factor (HNF) 4α, peroxisome proliferator-activated receptor (PPAR) α, and PPAR γ co-activator (PGC) 1α control the expression of GK. There is evidence that GK, in turn, directly or indirectly effects the expression or activity of downstream transcription factors such as glucocorticoid-glucocorticoid receptor complex (GR), HNF 4α, PPAR α, sterol regulatory element binding protein (SREBP) 1a, SREBP 2, and carbohydrate response element binding protein (ChREBP), which regulate their target genes. TF_u, TF_v, TF_x, and TF_y are hypothesized transcription factors. Dashed

lines indicate transcription factors that are currently unknown but may be identified in future studies.

Figure 2. Supervised hierarchical clustering "heat map" of the wild type (WT) and *GK*-overexpressing cell line (GK2). (a) Genes involved in cellular metabolic processes. **(b)** Genes involved in lipid metabolic processes and lipid transport. Genes were filtered by using the following criteria: absolute fold change > 1.5, absolute difference in expression level > 100, p < 0.05, present call > 20%. Genes with incomplete annotations ("transcribed locus" or "similar to *another gene*") were omitted. The two biological replicates of each cell line are shown separately. Red color indicates upregulation and green indicates downregulation, as denoted by the color bars below each panel.

Figure 3. Quantification of gene expression by quantitative PCR. Gene expression levels for the *GK*-overexpressing cell line (GK2) as compared to the wild type (WT). Black bars denote values obtained by microarray analysis and gray bars denote values by quantitative RT-PCR. Significant differences (p < 0.05) between lines GK2 and WT are indicated by '+' (microarray) and '*' (quantitative RT-PCR). Abbreviations: *IGFBP1*, insulin-like growth factor binding protein 1; *TyrAT*, tyrosine aminotransferase; *ADH*, alcohol dehydrogenase; *GluL*, glutamine synthetase/glutamate ammonia ligase; *IDH*, isocitrate dehydrogenase; *PEPCK*, phosphoenolpyruvate carboxykinase; *G6PDH*, glucose-6-phosphate dehydrogenase; *SREBF1*, sterol regulatory element binding factor 1; *ME*, malic enzyme; *hGK*, human *GK*. Genes that are regulated by glucocorticoid receptor (GR) or involved in lipogenesis are indicated.

Figure 4. Lipid visualization and quantification by Oil Red O staining. Wild type (WT)

and *GK*-overexpressing (GK2) cells were treated with Oil Red O as described in Methods.

(a) Cells after Oil Red O treatment, sample region from 10 cm plate. Intensity of red color is

proportional to lipid accumulation. **(b)** Absorbance of Oil Red O (at 510 nm) averaged

throughout a 10 cm plate. Significant differences are indicated "*" (p<0.01).

Figure 5. Activities of selected hepatically significant transcription factors in *GK*-

overexpressing cell line GK2, obtained by network component analysis (NCA) of

microarray data. Transcription factor activities are expressed as $\log_{10}$ of fold change with

respect to wild type. NCA was performed as explained in text. Abbreviations: SREBP, sterol

regulatory element binding protein; ChREBP, carbohydrate regulatory element binding

protein; HNF, hepatocyte nuclear factor; PPAR, peroxisome proliferator-activated receptor;

LXR, lever X receptor; C/EBP, CCAAT-box/enhancer binding protein; GR, activated

glucocorticoid-glucocorticoid receptor complex.

Figure 6. *GK*-overexpressing cell line GK2 has higher GR transcription factor activity

than the wild type (WT). WT (open circles) and GK2 (filled circles) cell lines were assayed

for glucocorticoid receptor transcription factor activity by measuring the expression level

of known GR-responsive gene PEPCK to glucocorticoid agonist dexamethasone for **(a)** 1 h

and **(b)** 2 h. Gene expression levels are relative to dexamethasone-untreated controls (0

nM) for the same line. '*' indicates $p < 0.05$ between different dexamethasone dosages on

the same cell line. '**' indicates $p < 0.05$ between lines GK2 and WT for the same

dexamethasone dosage. Gene expression was assayed by quantitative RT-PCR, as described

in Methods.

Figure 7. *GK* **overexpression mimics the effect of dexamethasone addition on GR transcription factor activity on wild type cells.** Line WT (open bars) was either untreated or treated with 200 nM dexamethasone for different times, and assayed for GR transcription factor activity. This is compared to dexamethasone-untreated line GK2 (filled bars). GR transcription factor activity was measured by quantifying the expression level of known GR-responsive genes **(a)** TAT and **(b)** PEPCK. Gene expression was assayed by quantitative RT-PCR, as described in Methods. Gene expression levels are relative to dexamethasone-untreated controls (0 nM) for line WT. '*' indicates $p < 0.05$ between corresponding bars.

Supplemental Material

Supplemental Material 1: [PDF file, Supplement 1 PCA results.pdf] Unsupervised clustering of 2902 most varying genes between the wild type (WT) and *GK*-overexpressing cell line (GK2). The two biological replicates of each cell line are shown separately. **(a)** Three-dimensional biplot. Open circles denote WT, filled circles denote the GK2. **(b)** Average linkage clustering dendrogram.

Supplemental Material 2: [Microsoft Excel file "Supplement 1 Raw microarray data.xls"]. Microarray data for lines WT and GK2, expressed as intensities of 31,099 Affymetrix probesets. CEL files for this data are uploaded to the National Institutes of Health Gene Expression Omnibus.

Supplemental Material 3: [Microsoft Excel file "Supplement 3a NCA connectivity matrix.xls" (Supplemental Material 3a) and PDF file "Supplement 3 NCA connectivity references.pdf" (Supplemental Material 3b)]. Supplemental material 3a contains the initial connectivity matrix linking potential transcription factors to genes differentially expressed in GK2 cells, as compared to line WT. Sheet 1 contains the connectivity matrix and expression levels of genes. An entry of '1' in the connectivity matrix indicates that the corresponding transcription factor is known to regulate the corresponding gene; an entry of '0' indicates no known regulation. All '1' entries are supported by literature references, which are indicated by two-letter codes alongside the entry. Supplemental material 3b contains a listing of these references.

Supplemental Material 4: [Microsoft Excel file "Supplement 4 NCA results.xls"]. Output of NCA. The block B3–J4 contains transcription factor activities (of arbitrary sign) deduced by

NCA for the two biological replicates of line GK2, and the block B10–J61 contains connectivity strengths (also deduced by NCA) between the transcription factors listed in B2–J2 and the genes listed in A10–A61. We multiplied the entire NCA-deduced column for each transcription factor (that contains the activity of and all connectivity strengths corresponding to the transcription factor) by an appropriate sign (either –1 or +1). This multiplication was necessary because the NCA decomposition is unique up to a scaling factor and the decomposition algorithm does not directly determine the signs of the transcription factor activities and connectivity strengths that it calculates (Liao et al., 2003). This sign has to be determined on the basis of experimentally determined connectivity directions (up- or down- regulation) between that transcription factor and one or more of its genes. As an illustration, in case of PPARα there is experimental evidence in Tamura et al. (2006) that PPARα negatively regulates the genes cadherin 17; procollagen, type III, alpha 1; and procollagen, type V, alpha 2 (Tamura et al., 2006). However, the initial NCA output (column G) shows positive signs for the connectivity strengths between PPARα and all these three genes; therefore, the entire PPARα column (transcription factor activities and connectivity strengths; column G) should be multiplied by –1 to be consistent with experimental connectivity evidence in Tamura et al. (2006). The sign-corrected column thus obtained (and reported in the paper) is column Q. This multiplication was performed for all transcription factors on the basis of experimental information available for the genes indicated with thick borders, the experimental connectivity directions being obtained from the references listed in Supplemental Material 3A/3B. The transcription factor activities (and their means and standard deviations) as well as connectivity strengths with correct signs are reported in the block L3–T61.

Figure 1

Figure 2

a

WT WT GK2 GK2

genotype 3 3 1 1

Activating transcription factor 7 (predicted)
phospholipase C, beta 1 /// phospholipase C, beta 1
dual specificity phosphatase 5
pleckstrin homology-like domain, family A, member 1
carnitine palmitoyltransferase 1b, muscle /// carnitine palmitoyltransferase 1b, muscle
Putative aminopeptidase Fxna
FBJ murine osteosarcoma viral oncogene homolog /// FBJ murine osteosarcoma viral oncogene homolog
B-cell translocation gene 2, anti-proliferative
peptidylglycine alpha-amidating monooxygenase
growth arrest and DNA-damage-inducible 45 gamma /// growth arrest and DNA-damage-inducible 45 gamma
spastic paraplegia 7 homolog (human)
nuclear receptor subfamily 4, group A, member 1 /// nuclear receptor subfamily 4, group A, member 1
dopa decarboxylase
ectonucleotide pyrophosphatase/phosphodiesterase 2
early growth response 1 /// early growth response 1
transforming growth factor beta 1 induced transcript 4 /// similar to transforming growth factor beta 1 induced transcript 4 isofor..
lipase, hepatic /// lipase, hepatic
PYD and CARD domain containing
inter-alpha trypsin inhibitor, heavy chain 3
histidine decarboxylase /// histidine decarboxylase
cytochrome P450, family 3, subfamily a, polypeptide 13 /// cytochrome P450, family 3, subfamily a, polypeptide 13
apolipoprotein C-I /// apolipoprotein C-I
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 (mapped) /// serine (or cystein..
prolactin receptor
Aryl hydrocarbon receptor nuclear translocator 2
cytochrome P450, family 2, subfamily e, polypeptide 1 /// cytochrome P450, family 2, subfamily e, polypeptide 1
Dual specificity phosphatase 6
deiodinase, iodothyronine, type II /// solute carrier family 25 (mitochondrial carrier, brain), member 14
nuclear receptor subfamily 4, group A, member 2
met proto-oncogene
selenophosphate synthetase 1
longevity assurance homolog 5 (S. cerevisiae) (predicted)
dyskeratosis congenita 1, dyskerin
pyrroline-5-carboxylate reductase-like
solute carrier family 29 (nucleoside transporters), member 1
ATP-binding cassette, sub-family A (ABC1), member 1
RNA guanylyltransferase and 5'-phosphatase (predicted)
glutamate cysteine ligase, modifier subunit /// glutamate cysteine ligase, modifier subunit
Tripartite motif protein 16 (predicted)
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide /// alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide
N-acylsphingosine amidohydrolase 1
activating transcription factor 3 /// activating transcription factor 3
acyl-Coenzyme A dehydrogenase family, member 11 (predicted)
Kruppel-like factor 5
lipocalin 7
clusterin /// clusterin
matrix metallopeptidase 24
epoxide hydrolase 1, microsomal /// epoxide hydrolase 1, microsomal
tyrosine aminotransferase /// tyrosine aminotransferase
adrenomedullin /// adrenomedullin
ATP-binding cassette, sub-family C (CFTR/MRP), member 2 /// ATP-binding cassette, sub-family C (CFTR/MRP), member 2
Alcohol dehydrogenase 1 (class I) /// Alcohol dehydrogenase 1 (class I)
NAD(P)H dehydrogenase, quinone 1 /// NAD(P)H dehydrogenase, quinone 1
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 /// serine (or cysteine) protein...
cerebellar degeneration-related 2 /// cerebellar degeneration-related 2
neuregulin 1 /// neuregulin 1
hydroxysteroid 11-beta dehydrogenase 1 /// tetraspanin 8
ATP-binding cassette, sub-family G (WHITE), member 8 /// ATP-binding cassette, sub-family G (WHITE), member 8
liver UDP-glucuronosyltransferase, phenobarbital-inducible form /// liver UDP-glucuronosyltransferase, phenobarbital-induci...
DNA-damage inducible transcript 3 /// DNA-damage inducible transcript 3
glutamate-cysteine ligase, catalytic subunit
complement component 3 /// complement component 3
sulfotransferase family 1B, member 1 /// sulfotransferase family 1B, member 1
sterol regulatory element binding factor 1
dimethylarginine dimethylaminohydrolase 1
monoamine oxidase B /// monoamine oxidase B
fatty acid binding protein 5, epidermal /// fatty acid binding protein 5, epidermal
J domain protein 1
Coenzyme Q6 homolog (yeast)
glutathione peroxidase 2 /// glutathione peroxidase 2
thyroid hormone receptor alpha
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1
protein kinase C, alpha /// protein kinase C, alpha
apolipoprotein B /// apolipoprotein B
S100 protein, beta polypeptide
phospholipase A2, group IB /// phospholipase A2, group IB
ST3 beta-galactoside alpha-2,3-sialyltransferase 4

-3.0 -1.0 1.0 3.0

b

GK2 GK2 WT WT

genotype 1 1 3 3

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide /// alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide
N-acylsphingosine amidohydrolase 1
phospholipase A2, group IB /// phospholipase A2, group IB
apolipoprotein B /// apolipoprotein B
sulfotransferase family 1B, member 1 /// sulfotransferase family 1B, member 1
clusterin /// clusterin
adrenomedullin /// adrenomedullin
fatty acid binding protein 5, epidermal /// fatty acid binding protein 5, epidermal
sterol regulatory element binding factor 1
hydroxysteroid 11-beta dehydrogenase 1 /// tetraspanin 8
ATP-binding cassette, sub-family G (WHITE), member 8 /// ATP-binding cassette, sub-family G (WHITE), member 8
alpha-2-HS-glycoprotein
Alcohol dehydrogenase 1 (class I) /// Alcohol dehydrogenase 1 (class I)
ceramide kinase (predicted)
ATP-binding cassette, sub-family A (ABC1), member 1
phospholipase C, beta 1 /// phospholipase C, beta 1
carnitine palmitoyltransferase 1b, muscle /// carnitine palmitoyltransferase 1b, muscle
lipase, hepatic /// lipase, hepatic
apolipoprotein C-I /// apolipoprotein C-I
prolactin receptor

-3.0 -1.0 1.0 3.0

Figure 3

Figure 4

a

WT

GK2

b

Figure 5

Figure 6

Figure 7

Table 1

Table 1. Principal genes differentially expressed in *GK*-overexpressing (GK2) cells with respect to the wild type (WT). Bolded entries are known GR-responsive genes. The column labeled *p* indicates the *p* value with respect to WT, as determined by a Student's *t*-test.

Gene	LocusLink	Fold change	*p*
albumin	24186	-124.00	0.00
procollagen, type III, alpha 1	84032	-105.46	0.02
glypican 3	25236	-34.71	0.00
lactate dehydrogenase B	24534	-32.70	0.02
apolipoprotein C-I	25292	-10.57	0.04
procollagen, type V, alpha 2	85250	-6.63	0.01
cadherin 17	117048	-5.63	0.00
ectonucleotide pyrophosphatase/phosphodiesterase 2	84050	-3.80	0.04
histidine decarboxylase	24443	-3.56	0.00
thrombospondin 1	445442	-3.16	0.02
cytochrome P450, family 2, subfamily e, polypeptide 1	25086	-2.80	0.02
B-cell linker	499356	-2.14	0.03
dual specificity phosphatase 6	116663	-1.97	0.00
neuropilin 1	246331	-1.96	0.03
glutamine synthetase/ glutamate-ammonia ligase (*GluL*)	**24957**	**-1.64**	**0.02**
carnitine palmitoyltransferase 1b, muscle	25756	-1.55	0.04
histone 1, H2bh	306945	-1.50	0.00
ATP-binding cassette, sub-family A, member 1 (*ABC1*)	**313210**	**1.18**	**0.05**
glucose-6-phosphate dehydrogenase (*G6PDH*)	24377	1.25	0.03
phosphoenolpyruvate carboxykinase 1 (*PEPCK1*)	**362282**	**1.29**	**0.01**
insulin-like growth factor binding protein 1 (*IGFBP1*)	**312320**	**1.30**	**0.05**
malic enzyme 1 (*ME1*)	24552	1.31	0.01
isocitrate dehydrogenase 1 (NADP+), soluble (*IDH1*)	24479	1.32	0.01
paraoxonase 3	312086	1.46	0.03
clusterin	24854	1.59	0.04
ectonucleoside triphosphate diphosphohydrolase 5	314312	1.61	0.01
tyrosine aminotransferase (*TyrAT*)	**24813**	**1.69**	**0.03**
glutamate-cysteine ligase, catalytic subunit	25283	1.75	0.00
sterol regulatory element binding factor 1 (*SREBF1*)	78968	1.80	0.04
apolipoprotein B	54225	1.85	0.03
alpha-2-HS-glycoprotein	25373	1.92	0.00
adrenomedullin	**25026**	**2.06**	**0.03**

Gene	LocusLink	Fold change	p
alcohol dehydrogenase 1 (class I) (*ADH1*)	24172	**2.17**	0.04
BH3 interacting (with BCL2 family) domain, apoptosis agonist	117271	2.21	0.03
phospholipase A2, group IB	29526	2.23	0.01
11-beta hydroxysteroid dehydrogenase 1/tetraspanin 8	25116	2.31	0.00
liver UDP-glucuronosyltransferase, phenobarbital-inducible form	286954	2.33	0.00
Kruppel-like factor 5	84410	2.43	0.03
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 (*Serpina1a*)	24648	**2.56**	**0.00**
huntingtin-associated protein 1	29430	2.90	0.00
glutathione peroxidase 2	29326	4.99	0.01

a

3rd principal component

20
15
10
5
0

-25
-20
-15
-10
-5

1st principal component

-40
-20
0
20
40

2nd principal component

○ WT
○ WT
● GK1
● GK1

b

Linkage distance

60
50
40
30
20
10
0

WT   WT   GK1   GK1

Supplemental Material 2

Probeset	WT/replicate 1		WT/replicate 2		GK2/replicate 1		GK2/replicate 2	
	Intensity	Call	Intensity	Call	Intensity	Call	Intensity	Call
AFFX-BioB-5_at	382.9	P	343.3	P	441.4	P	389.7	P
AFFX-BioB-M_at	567.2	P	525.3	P	477.3	P	507	P
AFFX-BioB-3_at	329.6	P	281.4	P	277	P	251	P
AFFX-BioC-5_at	1123.4	P	959.7	P	1036	P	1077.4	P
AFFX-BioC-3_at	1223.6	P	1116.6	P	1101.5	P	1167.8	P
AFFX-BioDn-5_at	2085.8	P	1872.6	P	2257.1	P	1934	P
AFFX-BioDn-3_at	4884.1	P	4845	P	4910.4	P	5250	P
AFFX-CreX-5_at	14234.4	P	12279.9	P	12233.5	P	12576.4	P
AFFX-CreX-3_at	18868.9	P	16696.8	P	14962.8	P	17203.8	P
AFFX-DapX-5_at	270.3	P	275.9	P	392.2	P	404.1	P
AFFX-DapX-M_at	933.8	P	1090.4	P	1302.8	P	1269.4	P
AFFX-DapX-3_at	1709.1	P	1657.4	P	2339.1	P	2530.3	P
AFFX-LysX-5_at	56.7	P	74.2	P	88.6	P	83.8	P
AFFX-LysX-M_at	132.1	P	138.3	P	187.6	P	155.2	P
AFFX-LysX-3_at	336.2	P	263.1	P	285.8	P	355.9	P
AFFX-PheX-5_at	119.7	P	96.2	P	120.7	P	137.4	P
AFFX-PheX-M_at	124.4	P	99.4	P	154	P	137.4	P
AFFX-PheX-3_at	307.7	P	288.4	P	293.9	P	357.5	P
AFFX-ThrX-5_at	102.3	P	60.2	P	98.5	P	115.3	P
AFFX-ThrX-M_at	137.1	P	167.9	P	176.1	P	191.6	P
AFFX-ThrX-3_at	464.3	P	514.2	P	576.1	P	665.3	P
AFFX-TrpnX-5_at	7	A	23.2	A	11.6	A	11.4	A
AFFX-TrpnX-M_at	3.4	A	3.3	A	3.1	A	4.8	A
AFFX-TrpnX-3_at	2.7	A	2.1	A	2.1	A	9.6	A
AFFX-r2-Ec-bioB-5_at	569.7	P	396.1	P	469	P	500.5	P
AFFX-r2-Ec-bioB-M_at	574	P	529.7	P	508.5	P	557.5	P
AFFX-r2-Ec-bioB-3_at	524.4	P	485.9	P	488.6	P	522.8	P
AFFX-r2-Ec-bioC-5_at	1704.8	P	1387.6	P	1522.2	P	1703	P
AFFX-r2-Ec-bioC-3_at	1440.9	P	1319.4	P	1465.3	P	1635.9	P
AFFX-r2-Ec-bioD-5_at	6446.9	P	6148.4	P	6292.9	P	7171.1	P
AFFX-r2-Ec-bioD-3_at	7863.5	P	7753.5	P	7754.8	P	8078.8	P
AFFX-r2-P1-cre-5_at	21554	P	20466.8	P	19183	P	21739	P
AFFX-r2-P1-cre-3_at	26280.4	P	24884.6	P	22101.2	P	26629.1	P
AFFX-r2-Bs-dap-5_at	366.5	P	355.6	P	540.9	P	495.3	P
AFFX-r2-Bs-dap-M_at	860.2	P	947.2	P	1031.3	P	1210.3	P
AFFX-r2-Bs-dap-3_at	1544.5	P	1778.7	P	2030.1	P	2041.3	P
AFFX-r2-Bs-lys-5_at	96.6	P	98.9	P	135.6	P	137.9	P
AFFX-r2-Bs-lys-M_at	94.7	P	93	P	100.8	P	131.2	P
AFFX-r2-Bs-lys-3_at	137.4	P	130.1	P	134.1	P	180.4	P
AFFX-r2-Bs-phe-5_at	121.7	P	112.4	P	185.7	P	140.9	P
AFFX-r2-Bs-phe-M_at	145	P	137.1	P	145.3	P	191.1	P
AFFX-r2-Bs-phe-3_at	353.6	P	343.3	P	283.1	P	369.1	P
AFFX-r2-Bs-thr-5_s_at	135.1	P	158.2	P	241.9	P	211.7	P
AFFX-r2-Bs-thr-M_s_at	297.3	P	316	P	299.9	P	362.1	P
AFFX-r2-Bs-thr-3_s_at	655.3	P	556.5	P	745.2	P	892.7	P

gene	SREBP1a	SREBP1c	SREBP2	ChREBP	Sp1
Acetyl-coenzyme A acetyltransferase 1	0	0	0	0	0
Activating transcription factor 2	0	0	0	0	0
adrenomedullin /// adrenomedullin	0	0	0	0	0
albumin	0	0	0	0	0
albumin /// albumin	0	0	0	0	0
Alcohol dehydrogenase 1 (class I) /// Alcohol dehydrogenase 1 (cl:	1 aa	0	1 aa	0	0
aldo-keto reductase family 1, member B8 /// aldo-keto reductase f:	0	0	0	0	0
aldo-keto reductase family 1, member C12 (predicted)	0	0	0	0	0
alpha-2-HS-glycoprotein	0	0	0	0	0
annexin A5 /// annexin A5	0	0	0	0	0
apolipoprotein B /// apolipoprotein B	0	0	0	0	0
apolipoprotein C-I /// apolipoprotein C-I	1 aa	0	0	0	0
arsenic (+3 oxidation state) methyltransferase	0	0	0	0	0
ATP-binding cassette, sub-family A (ABC1), member 1 /// ATP-bin	0	0	0	0	0
cadherin 17	0	0	0	0	0
carnitine palmitoyltransferase 1b, muscle /// carnitine palmitoyltr	0	0	0	0	0
clusterin /// clusterin	1 aa	0	0	0	0
cytochrome P450, family 1, subfamily a, polypeptide 2 /// cytochrc	0	0	0	0	0
cytochrome P450, family 2, subfamily c, polypeptide 23 /// cytochr	0	0	0	0	0
cytochrome P450, family 2, subfamily e, polypeptide 1 /// cytochrc	0	0	0	0	0
cytochrome P450, family 3, subfamily a, polypeptide 13 /// cytochr	0	0	0	0	0
dopa decarboxylase	0	0	0	0	0
ectonucleoside triphosphate diphosphohydrolase 5	0	0	0	0	0
ectonucleotide pyrophosphatase/phosphodiesterase 2	0	0	0	0	0
glucose-6-phosphate dehydrogenase	1 ae,	1 ae,	1 ae	1 ai, l	1
glutamate-ammonia ligase (glutamine synthetase)	0	0	0	0	0
glutathione peroxidase 2 /// glutathione peroxidase 2	0	0	0	0	0
glutathione reductase /// glutathione reductase	1 aa	0	0	0	0
glutathione S-transferase theta 1 /// glutathione S-transferase thet	1 aa	0	0	0	0
glypican 3	0	0	0	0	0
histidine decarboxylase /// histidine decarboxylase	0	0	0	0	0
hydroxysteroid 11-beta dehydrogenase 1 /// tetraspanin 8	1 aa	0	0	0	0
insulin-like growth factor binding protein 1 /// insulin-like growth	0	0	0	0	0
isocitrate dehydrogenase 1 (NADP+), soluble	1 aa	0	1 aa	0	0
Kruppel-like factor 5	0	0	0	0	1
Kruppel-like factor 5	0	0	0	0	1
lipase, hepatic /// lipase, hepatic	0	0	0	0	0
malic enzyme 1	1 aa	0	1 aa	1 ai, l	1
malic enzyme 1 /// malic enzyme 1	1 aa	0	1 aa	1 ai, l	1
paraoxonase 3	0	0	0	0	0
phosphoenolpyruvate carboxykinase 1 /// phosphoenolpyruvate c	1 aa	0	0	1 ai	0
procollagen, type III, alpha 1 /// procollagen, type III, alpha 1	0	0	0	0	0
procollagen, type V, alpha 2	0	0	0	0	0
procollagen, type V, alpha 2	0	0	0	0	0
serine (or cysteine) peptidase inhibitor, clade D, member 1 /// seri	0	0	0	0	0
serine (or cysteine) peptidase inhibitor, clade G, member 1 /// seri	0	0	0	0	0
serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiprote	0	0	0	0	0
similar to solute carrier family 17 (sodium phosphate), member 4 /	0	0	0	1 bj	0
solute carrier family 22 (organic cation transporter), member 1	0	0	0	0	0
Solute carrier family 26 (sulfate transporter), member 1	0	0	0	0	0
sterol regulatory element binding factor 1	1 aa	0	1 aa	1 ai	0
sterol regulatory element binding factor 1 /// sterol regulatory eler	1 aa	0	1 aa	1 ai	0
Thrombospondin 1	0	0	0	0	1

References for NCA connectivity matrix

Number	Reference
aa	(Horton et al. 2003)
ab	(Herzog et al. 2004)
ac	(Mascaro et al. 1998)
ad	(Banine et al. 2000)
ae	(Amemiya-Kudo et al. 2002)
af	(Le et al. 2005)
ag	(Mandard et al. 2004)
ah	(Hiraku Ono et al. 2003)
ai	(Katsumi Iizuka et al. 2004)
aj	(Chu et al. 2004)
ak	(Peters et al. 2005)
al	(Cherkaoui-Malki et al. 2001)
am	(Stier et al. 1998)
an	(Mittelstadt and Ashwell 2003)
ao	(Kersten et al. 2001)
ap	(Iritani 2000)
aq	(Xu et al. 2004)
ar	(Schoneveld et al. 2004)
as	(Shingu and Bornstein 1994)
at	http://www.sladeklab.ucr.edu/hnf43.pdf
au	(Leone et al. 1999)
av	(Trautwein et al. 1996)
aw	(Mueller 1992)
ax	(Ruminy et al. 2001)
ay	(Ronggai Sun et al. 2001)
az	(Hinoi et al. 2002)
ba	(Martelli et al. 1994)
bb	(Moya-Garcia et al. 2005)
bc	(J D Horton et al. 1998)
bd	(Lu and Cidlowski 2005)
be	(Cortes-Canteli et al. 2004)
bf	(Guo et al. 2006)
bg	(Leclerc et al. 2004)
bh	(Odom et al. 2004)
bi	(Seckl and Walker 2001)
bj	(Lin Ma et al. 2006)
bk	(Friedman et al. 2004)
bl	(Harmancey et al. 2007)
bm	(Rebouissou et al. 2007)

bn	(Hayhurst et al. 2001)
bo	(K Tamura et al. 2006)
bp	(Tien et al. 2003)
bq	(Shishido et al. 2003)
br	(Spear et al. 2006)
bs	(You et al. 2003)
bt	(Ceshi Chen et al. 2004)
bu	(Quinet et al. 2006)
bv	(Maxwell et al. 2003)
bw	(Edwards et al. 2002)
bx	(Ide et al. 2003)
by	(Repa and DJ Mangelsdorf 2003)
bz	(Peet et al. 1998)
ca	(Mitro et al. 2007)
cb	(Steffensen and Gustafsson 2004)
cc	(Krook 2006)
cd	(Fahrner et al. 1993)
ce	(Griffo et al. 1993)
cf	(Gotoh et al. 1997)
cg	(Thomas P. Burris et al. 2005)

Bibliography

"HNF4{alpha} target genes." http://www.sladeklab.ucr.edu/hnf43.pdf.

Amemiya-Kudo, Michiyo et al. 2002. "Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes." *J. Lipid Res.* 43:1220-1235.

Banine, Fatima, Christophe Gangneux, Louis Mercier, Alphonse Le Cam, and Jean-Philippe Salier. 2000. "Positive and negative elements modulate the promoter of the human liver-specific alpha2-HS-glycoprotein gene." *European Journal of Biochemistry* 267:1214-1222.

Burris, Thomas P. et al. 2005. "The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand." *Mol Pharmacol* 67:948-954.

Chen, Ceshi et al. 2004. "Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells." *Gene* 330:133-142.

Cherkaoui-Malki, M et al. 2001. "Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis." *Gene Expression* 9:291-304.

Chu, Ruiyin et al. 2004. "Protein profiling of mouse livers with peroxisome proliferator-activated receptor {alpha} activation." *Mol. Cell. Biol.* 24:6288-6297.

Cortes-Canteli, Marta, Mechthild Wagner, Wilhelm Ansorge, and Ana Perez-Castillo. 2004. "Microarray analysis supports a role for CCAAT/enhancer-binding protein-{beta} in brain injury." *J. Biol. Chem.* 279:14409-14417.

Edwards, Peter A., Matthew A. Kennedy, and Puiying A. Mak. 2002. "LXRs; : Oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis." *Vascular Pharmacology* 38:249-256.

Fahrner, Joachim et al. 1993. "Identification and functional characterization of regulatory elements of the glutamine synthetase gene from rat liver." *European Journal of Biochemistry* 213:1067-1073.

Friedman, Joshua R. et al. 2004. "Orthogonal analysis of C/EBP{beta} targets in vivo during liver proliferation." *Proceedings of the National Academy of Sciences* 101:12986-12991.

Gotoh, Tomomi, Shoaib Chowdhury, Masaki Takiguchi, and Masataka Mori. 1997. "The glucocorticoid-responsive gene cascade. Activation of the rat arginase gene through induction of C/EBP{beta}." *J. Biol. Chem.* 272:3694-3698.

Griffo, G et al. 1993. "HNF4 and HNF1 as well as a panel of hepatic functions are extinguished and reexpressed in parallel in chromosomally reduced rat hepatoma-human fibroblast hybrids." *J. Cell Biol.* 121:887-898.

Guo, Lei et al. 2006. "Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells." *Molecular Diversity* 10:349-360.

Harmancey, Romain, Jean-Michel Senard, Philippe Rouet, Atul Pathak, and Fatima Smih. 2007. "Adrenomedullin inhibits adipogenesis under transcriptional control of insulin." *Diabetes* 56:553-563.

Hayhurst, Graham P., Ying-Hue Lee, Gilles Lambert, Jerrold M. Ward, and Frank J. Gonzalez. 2001. "Hepatocyte nuclear factor 4{alpha} (nuclear receptor 2a1) is essential for maintenance of hepatic gene expression and lipid homeostasis." *Mol. Cell. Biol.* 21:1393-1403.

Herzog, Birger, Robert K. Hall, Xiaohui L. Wang, Mary Waltner-Law, and Daryl K. Granner. 2004. "Peroxisome proliferator-activated receptor {gamma} coactivator-1{alpha}, as a transcription amplifier, is not essential for basal and hormone-induced phosphoenolpyruvate carboxykinase gene expression." *Mol Endocrinol* 18:807-819.

Hinoi, Takao et al. 2002. "CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia." *Gastroenterology* 123:1565-1577.

Horton, J D et al. 1998. "Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2." *Journal of Clinical Investigation* 101:2331-2339.

Horton, Jay D. et al. 2003. "Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes." *Proceedings of the National Academy of Sciences* 100:12027-12032.

Ide, Tomohiro et al. 2003. "Cross-talk between peroxisome proliferator-activated receptor (PPAR) {alpha} and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling." *Mol Endocrinol* 17:1255-1267.

Iizuka, Katsumi, Richard K. Bruick, Guosheng Liang, Jay D. Horton, and Kosaku Uyeda. 2004. "Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis." *Proceedings of the National Academy of Sciences* 101:7281-7286.

Iritani, N. 2000. "Nutritional and insulin regulation of leptin gene expression." *Current opinion in clinical nutrition and metabolic care* 3:275-9.

Kersten, S et al. 2001. "The peroxisome proliferator-activated receptor {alpha} regulates amino acid metabolism." *FASEB J.* 15:1971-1978.

Krook, A. 2006. "Can the liver X receptor work its magic in skeletal muscle too?." *Diabetologia* 49:819-821.

Le, Phillip Phuc et al. 2005. "Glucocorticoid receptor-dependent gene regulatory networks." *PLoS Genetics* 1:e16.

Leclerc, N et al. 2004. "Gene expression profiling of glucocorticoid-inhibited osteoblasts." *J Mol Endocrinol* 33:175-193.

Leone, Teresa C., Carla J. Weinheimer, and Daniel P. Kelly. 1999. "A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: The PPARalpha -null mouse as a model of fatty acid oxidation disorders." *Proceedings of the National Academy of Sciences* 96:7473-7478.

Lu, Nick Z., and John A. Cidlowski. 2005. "Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes." *Molecular Cell* 18:331-342.

Ma, Lin, Luke N. Robinson, and Howard C. Towle. 2006. "ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver." *J. Biol. Chem.* 281:28721-28730.

Mandard, S., M. Müller, and S. Kersten. 2004. "Peroxisome proliferator-activated receptor a target genes." *Cellular and Molecular Life Sciences (CMLS)* 61:393-416.

Martelli, Alberto M. et al. 1994. "Phosphoinositide signaling in nuclei of friend cells: phospholipase C {beta} down-regulation is related to cell differentiation." *Cancer Res* 54:2536-2540.

Mascaro, Cristina et al. 1998. "Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor." *J. Biol. Chem.* 273:8560-8563.

Maxwell, Kara N., Raymond E. Soccio, Elizabeth M. Duncan, Ephraim Sehayek, and Jan L. Breslow. 2003. "Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice." *J. Lipid Res.* 44:2109-2119.

Mitro, Nico et al. 2007. "The nuclear receptor LXR is a glucose sensor." *Nature* 445:219-223.

Mittelstadt, Paul R., and Jonathan D. Ashwell. 2003. "Disruption of glucocorticoid receptor exon 2 yields a ligand-responsive C-terminal fragment that regulates gene expression." *Mol Endocrinol* 17:1534-1542.

Moya-Garcia, Aurelio A., Miguel Angel Medina, and Francisca Sanchez-Jimenez. 2005. "Mammalian histidine decarboxylase: from structure to function." *BioEssays* 27:57-63.

Mueller, C R. 1992. "The down-regulation of albumin transcription during regeneration is due to the loss of HNF-1 and the D-site transcription factors." *DNA and cell biology* 11:559-66.

Odom, Duncan T. et al. 2004. "Control of pancreas and liver gene expression by HNF transcription factors." *Science* 303:1378-1381.

Ono, Hiraku et al. 2003. "Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement." *Diabetes* 52:2905-2913.

Peet, Daniel J. et al. 1998. "Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR[alpha]." *Cell* 93:693-704.

Peters, Jeffrey, Connie Cheung, and Frank Gonzalez. 2005. "Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand?." *Journal of Molecular Medicine* 83:774-785.

Quinet, Elaine M. et al. 2006. "Liver X receptor (LXR)-{beta} regulation in LXR{alpha}-deficient mice: Implications for therapeutic targeting." *Mol Pharmacol* 70:1340-1349.

Rebouissou, Sandra et al. 2007. "HNF1{alpha} inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation." *J. Biol. Chem.* 282:14437-14446.

Repa, JJ, and DJ Mangelsdorf. 2003. "The role of orphan nuclear receptors in the regulation of cholesterol homeostasis." http://arjournals.annualreviews.org/doi/abs/10.1146%2Fannurev.cellbio.16.1.459 (Accessed May 19, 2008).

Ruminy, P. et al. 2001. "Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes." *Inflammation Research* 50:383-390.

Schoneveld, Onard J.L.M., Ingrid C. Gaemers, and Wouter H. Lamers. 2004. "Mechanisms of glucocorticoid signalling." *Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression* 1680:114-128.

Seckl, Jonathan R., and Brian R. Walker. 2001. "Minireview: 11{beta}-hydroxysteroid dehydrogenase type 1-- A tissue-specific amplifier of glucocorticoid action." *Endocrinology* 142:1371-1376.

Shingu, T, and P Bornstein. 1994. "Overlapping Egr-1 and Sp1 sites function in the regulation of transcription of the mouse thrombospondin 1 gene." *J. Biol. Chem.* 269:32551-32557.

Shishido, Shoichiro et al. 2003. "Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes." *Hepatology* 37:136-147.

Spear, B., L. Jin, S. Ramasamy, and A. Dobierzewska. 2006. "Transcriptional control in the mammalian liver: liver development, perinatal repression, and zonal gene regulation." *Cellular and Molecular Life Sciences (CMLS)* 63:2922-2938.

Steffensen, Knut R., and Jan-Ake Gustafsson. 2004. "Putative metabolic effects of the liver X receptor (LXR)." *Diabetes* 53:S36-42.

Stier, H et al. 1998. "Maturation of peroxisomes in differentiating human hepatoblastoma cells (HepG2): possible involvement of the peroxisome proliferator-activated receptor α (PPARα)." *Differentiation* 64:55-66.

Sun, Ronggai, Xinming Chen, and Vincent W. Yang. 2001. "Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation." *J. Biol. Chem.* 276:6897-6900.

Tamura, K, A Ono, T Miyagishima, T Nagao, and T Urushidani. 2006. "Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators." *Journal of Toxicological Sciences* 31:471-490.

Tien, Eric S, Joshua P Gray, Jeffrey M Peters, and John P Vanden Heuvel. 2003. "Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes." *Cancer research* 63:5767-80.

Trautwein, Christian et al. 1996. "C/EBP-beta/LAP controls down-regulation of albumin gene transcription during liver regeneration." *J. Biol. Chem.* 271:22262-22270.

Xu, Jun et al. 2004. "Peroxisomal proliferator-activated receptor {alpha} deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux." *Endocrinology* 145:1087-1095.

You, Kyung-Ran, Ming-Jie Liu, Xue-Ji Han, Zee-Won Lee, and Dae-Ghon Kim. 2003. "Transcriptional regulation of the human transferrin gene by GADD153 in hepatoma cells." *Hepatology* 38:745-755.

Gene	SREBP1a	ChREBP	Sp1	HNF1α	HNF4α	PPARα	LXRα
			Transcription factor activities and statistics (arbitrary				
TF activity, GK2 (rep. 1)	0.5012	1.6614	0.4408	0.1840	0.5196	-0.3189	-0.5009
TF activity, GK2 (rep. 2)	0.4758	1.6923	0.4651	0.1674	0.5422	-0.3408	-0.4793
Mean TF activity							
SD of TF activity							
Multiplier	-1.0000	1.0000	1.0000	1.0000	1.0000	-1.0000	-1.0000
				Multipliers (-1 or +1) of each TF col			
			Connectivity strengths (abitrary sign)				
3-hydroxy-3-methylglutaryl-Coenzyme	0.0000	0.0000	0.0000	0.0000	0.0000	-0.1183	0.0000
acetyl-coenzyme A acetyltransferase 1	0.0000	0.0000	0.0000	0.0000	0.0000	0.2009	0.0000
activating transcription factor 2	0.0000	0.0000	0.0000	0.2469	0.0000	0.0000	0.0000
adrenomedullin /// adrenomedullin	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
aldo-keto reductase family 1, member	0.0000	0.0000	0.0000	0.0000	0.0000	-0.2350	0.0000
aldo-keto reductase family 1, member	0.0000	0.0000	0.0000	0.0000	0.0000	0.3016	0.0000
alpha-2-HS-glycoprotein	0.0000	0.0000	0.0000	0.7895	0.2721	0.0000	0.0000
apolipoprotein B /// apolipoprotein B	0.0000	0.0000	0.0000	0.0000	0.4569	0.0000	0.0000
apolipoprotein C-I /// apolipoprotein C	-3.1589	0.0000	0.0000	0.0000	0.0000	0.0000	-1.0585
apolipoprotein C-III	0.0000	0.0000	0.0000	0.0000	-0.6019	-0.9681	0.0000
arsenic (+3 oxidation state) methyltrar	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
ATP-binding cassette, sub-family A (AB	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	-2.1404
ATP-binding cassette, sub-family A (AB	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	-0.4109
cadherin 17	0.0000	0.0000	0.0000	0.0000	0.0000	2.3671	0.0000
catalase /// catalase	0.0000	0.0000	0.0000	0.0000	0.0000	-0.2869	0.0000
clusterin /// clusterin	0.4730	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
cytochrome P450, family 1, subfamily	0.0000	0.0000	0.0000	2.1624	0.0000	0.0000	0.0000
cytochrome P450, family 1, subfamily	0.0000	0.0000	0.0000	-0.2192	0.3577	0.0000	0.0000
cytochrome P450, family 2, subfamily	0.0000	0.0000	0.0000	0.0000	0.1508	0.0000	0.0000
cytochrome P450, family 2, subfamily	0.0000	0.0000	0.0000	-1.5177	0.0000	0.0000	0.0000
cytochrome P450, family 3, subfamily	0.0000	0.0000	0.0000	0.0000	0.0000	0.7322	0.0000
cytochrome P450, family 4, subfamily	0.0000	0.0000	0.0000	0.0000	0.2982	0.4795	0.0000
dopa decarboxylase	0.0000	0.0000	0.0000	-0.4144	0.0000	0.0000	0.3902
ectonucleoside triphosphate diphosph	0.0000	0.0000	0.0000	1.0401	0.0000	0.0000	0.0000
ectonucleotide pyrophosphatase/phos	0.0000	0.0000	0.0000	-2.6842	0.0000	0.0000	0.0000
glutamate-ammonia ligase (glutamine	0.0000	0.0000	0.0000	0.0000	0.0000	-0.8907	0.0000
glutathione peroxidase 2 /// glutathio	0.0000	0.0000	0.0000	3.2827	0.0000	0.0000	0.0000
glutathione reductase /// glutathione	0.2271	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
glutathione S-transferase kappa 1	0.0000	0.0000	0.0000	0.3460	0.0000	0.0000	0.0000
glutathione S-transferase theta 1 /// g	-0.2711	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
heme oxygenase (decycling) 1 /// hem	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
histidine decarboxylase /// histidine de	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
hydroxysteroid 11-beta dehydrogenas	0.8700	0.0000	0.0000	-0.8097	0.0000	-0.2458	0.0000
immediate early response 2	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000
insulin-like growth factor binding prote	0.0000	0.0000	0.0000	0.2387	0.0000	0.0000	0.0000
Kruppel-like factor	0.0000	0.0000	1.1223	0.0000	0.0000	0.0000	0.0000
lipase, hepatic /// lipase, hepatic	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000